<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOXACURIUM CHLORIDE</span><br/>(dox'a-cur-i-um)<br/><span class="topboxtradename">Nuromax<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">skeletal muscle relaxant, nondepolarizing agent</span><br/><b>Prototype: </b>Tubocurarine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting neuromuscular blocking agent. Binds competitively to cholinergic receptors on the motor end-plate, thus resulting
         in a block of neuromuscular transmission. Most patients require a pharmacologic reversal prior to full spontaneous recovery
         from a neuromuscular block using an anticholinesterase.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces skeletal muscle relaxation during surgery.</p>
<h1><a name="uses">Uses</a></h1>
<p>Skeletal muscle relaxation during surgery after induction with general anesthesia.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Facilitates endotracheal intubation.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to doxacurium, pregnancy (category C), or children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Neuromuscular diseases (e.g., myasthenia gravis); burn patients; acidbase or serum electrolyte imbalances; newborn infants,
         older adults, lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Intubation or Induction</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.05 mg/kg administered as rapid bolus injection over 510 s. Use lower doses in older adults or patients with renal
               or hepatic dysfunction<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>212 y</i>, 0.030.05 mg/kg with halothane general anesthesia<br/><br/><span class="indicationtitle">Maintenance with General Anesthesia</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>212 y</i>, same dose as adult, but may have to give more frequently; 0.00050.01 mg/kg q60100min administered as rapid bolus
               injection over 510 s (dosing interval adjusted for each individual patient; use lower dosage in patients with renal
               or hepatic dysfunction)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute each 1 mL (1 mg) with 10 mL of D5W, NS, D5/NS, LR, or D5/LR to yield 0.1 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give IV push over 510 s.   Individualize doses according to age, body size, and presence of kidney, liver, and neuromuscular diseases. 
                  								Note: Doxacurium contains benzyl alcohol, which has been associated with fatal complications in newborns.
                  							 Doxacurium should be administered under the supervision of expert clinicians.  See manufacturer's guidelines for dilution, compatibility, and administration. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store undiluted at room temperature 15°25° C (41°77° F). Do not freeze. Diluted drug may be
            stored in polypropylene syringes for up to 24 h at 5°25° C (41°77° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Bradycardia, hypotension, cutaneous flushing, histamine release. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">volatile anesthetics</span>
<b>(isoflurane,</b>
<b>enflurane,</b>
<b>halothane)</b> potentiate the effects of doxacurium, requiring a reduced dose of doxacurium. Certain <span class="classification">antibiotics</span>, including the <span class="classification">aminoglycosides</span>, <b>capreomycin,</b>
<b>tetracycline,</b>
<b>bacitracin,</b>
<b>polymyxins,</b>
<b>lincomycin,</b>
<b>clindamycin,</b> and <b>colistin,</b> increase the neuromuscular blocking effect of doxacurium. <b>Carbamazepine</b> or <b>phenytoin</b> may increase the onset and decrease the duration of neuromuscular blockade. <b>Lithium,</b>
<b>magnesium,</b>
<b>procainamide,</b> or <b>quinidine</b> may enhance neuromuscular blockade. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 510 min. <span class="typehead">Peak:</span> 10 min. <span class="typehead">Duration:</span> 60160 min depending on dose. <span class="typehead">Distribution:</span> 30% protein bound. <span class="typehead">Metabolism:</span> Minimal to no hepatic metabolism. <span class="typehead">Elimination:</span> 4050% excreted in urine within 12 h. some excretion in bile. <span class="typehead">Half-Life:</span> 1.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for evidence of prolonged neuromuscular block which may range from skeletal muscle weakness to prolonged paralysis
            with respiratory insufficiency and apnea.
         </li>
<li>Monitor for full recovery of skeletal muscle function. Support ventilation until full recovery occurs.</li>
<li>
            							Note: Duration of neuromuscular block may be longer in persons &gt;60 years old and in obese patients whose doses have not been adjusted
            according to ideal body weight.
            						
         </li>
<li>Monitor accordingly, knowing that drugs used to antagonize doxacurium may wear off before the effects of doxacurium.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>